References of "CAVALIER, Etienne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailInadéquation du facteur ethnique pour l’estimation du débit de filtration glomérulaire en population générale noire-africaine : résultats en Côte d’Ivoire.
Sagou Yayo, Eric; Aye, E; Konan, JL et al

in Néphrologie & Thérapeutique (2016), 12(6), 454-459

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailBone markers during acute burn care: Relevance to clinical practice?
ROUSSEAU, Anne-Françoise ULg; Damas, Pierre ULg; DELANAYE, Pierre ULg et al

in Burns : Journal of the International Society for Burn Injuries (2016)

OBJECTIVE: Bone changes are increasingly described after burn. How bone markers could help to detect early bone changes or to screen burn patients at higher risk of demineralization is still not made ... [more ▼]

OBJECTIVE: Bone changes are increasingly described after burn. How bone markers could help to detect early bone changes or to screen burn patients at higher risk of demineralization is still not made clear. We performed an observational study assessing the changes in serum bone markers after moderate burn. METHODS: Adults admitted in the first 24h following burn extended on >10% body surface area were included. Serum levels of collagen type 1 cross-linked C-telopeptide (CTX), tartrate-resistant acid phosphatase 5b (TRAP), type 1 procollagen N-terminal (P1NP) and bone alkaline phosphatase (b-ALP) were measured at admission and every week during the first month. Data are expressed as median [min-max]. RESULTS: Bone markers were measured in 20 patients: 18 men, 2 women (including one post-menopausal). Age was 46 [19-86] years old, burn surface area reached 15 [7-85] %. Twelve patients completed the study. All biomarkers mainly remained into normal ranges during evolution. A huge variability was observed regarding biomarkers evolution. Patient's evolution was not linear and could fluctuate from a decrease to an increase of blood concentrations. There was not necessarily a consistency between the two formation or the two resorption markers. Variations observed between two consecutive measurements were lesser than the accepted critical difference in almost one third of the cases. CONCLUSIONS: Considering available data, role and interest of bone markers in management of burn related bone disease remain unclear. [less ▲]

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailIncidence of bone fractures after critical illness
ROUSSEAU, Anne-Françoise ULg; Michel, Laure ULg; Bawin, Maxime ULg et al

in Intensive Care Medicine Experimental (2016), 4(Suppl 1), 1131

Detailed reference viewed: 23 (12 ULg)
Full Text
Peer Reviewed
See detailSclérostine & insuffisance rénale: que nous apprennent les différents méthodes de dosage?
PAQUOT, Francois ULg; BOUQUEGNEAU, Antoine ULg; CAVALIER, Etienne ULg et al

in Néphrologie & Thérapeutique (2016), 12(5), 374

Detailed reference viewed: 19 (4 ULg)
Full Text
Peer Reviewed
See detailCystatin C standardization decreases assay variation and improves assessment of GFR
Ebert, N; DELANAYE, Pierre ULg; Shlipak, M et al

Poster (2016)

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailHigh serum sclerostin levels are associated with a better outcome in haemodialysis patients
Jean, Guillaume; Chazot, Charles; Bresson, Eric et al

in Nephron. Clinical Practice (2016)

Sclerostin is an osteocyte hormone that de- creases osteoblastogenesis. Sclerostin may play a key role in osteoporosis and also in vascular calcification (VC). In chron- ic kidney disease and ... [more ▼]

Sclerostin is an osteocyte hormone that de- creases osteoblastogenesis. Sclerostin may play a key role in osteoporosis and also in vascular calcification (VC). In chron- ic kidney disease and haemodialysis (HD) patients, serum sclerostin levels are high. Aim: To assess the correlation of serum sclerostin levels with VC, bone mineral density (BMD), and survival rate in HD patients. Methods: A cross-sectional study was conducted in prevalent HD patients to correlate serum sclerostin tertiles with the Kauppila aortic calcification score, BMD scores and survival rate. Results: We studied 207 patients who had a mean serum sclerostin level of 1.9 ± 0.7 ng/ml. Compared to patients in the 1st tertile of serum sclerostin levels (0.6–1.53 ng/ml), patients in the 3rd tertile (2.2–4.6 ng/ml) were significantly older (73.7 ± 12 vs. 64.7 ± 18 years), more frequently of the male gender (74 vs. 48%), had lower serum bone-specific alkaline phosphatases values (14 ± 9 vs. 20.4 ± 13 µg/l), were less frequently treated with alfacalcidol, displayed lower aortic calcification scores (9.5 ± 5 vs. 12.5 ± 7/24) and had higher BMD scores. Furthermore, patients of the 3rd tertile displayed a lower mortality rate compared to tertile 1 using multivariable adjusted Cox mod- el (hazard ratio 0.5, 95% CI 0.25–0.93, p = 0.03). The main fac- tors associated with VC score were age, diabetes, cardiovas- cular disease, CRP level and Warfarin use. Conclusion: Our study of HD patients shows that higher serum sclerostin lev- els are associated with higher BMD, lower aortic calcification scores, and a better survival rate. [less ▲]

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailBrain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations
CAVALIER, Etienne ULg; Carlisi, A.S.; WATAR, Florence ULg et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 116

Detailed reference viewed: 16 (8 ULg)
Full Text
Peer Reviewed
See detailEfficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Fafin, Coraline et al

in Journal of Nephrology (2016), 29(1), 99-103

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies ... [more ▼]

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies. We aimed to study the performance of DOT versus home medication. We follow the impact of providing native vitamin D directly by the nurse after a dialysis session on the 25-hydroxyvitamin [25(OH)D] concentrations. Methods In this observational study, we included 38 dialysis patients treated by stable dosage of cholecalciferol. DOT was implemented in December 2010. We considered the concentrations of 25-OH vitamin D three times before (T1 = June 2010, T2 = July 2010 and T3 = September 2010) and three times after the modification of prescription (T4 = February 2011, T5 = March 2011 and T6 = April 2011). Results Median age was 72 [62; 79] years and 48 % were diabetics. Mean body mass index was 26 ± 5 kg/m2 and median dialysis vintage was 20 [8; 46] months. The patients were compared to themselves. Before DOT, median concentrations of 25(OH)D were 27 (14–36), 23 (17–31), 31 (22–38) ng/mL at T1, T2 and T3, respectively. When DOT was effective, the concentrations significantly increased to 34 (28–44), 35 (29–41), 39 (32–47) ng/mL at T4, T5 and T6, respectively. Before DOT, 19 patients (50 %) reached the target of 30 ng/mL. After DOT, 29 patients (76 %) reached the target concentration of 30 ng/ mL. Conclusions In hemodialysis patients, DOT is both simple and effective to increase the therapeutic impact to native vitamin D. [less ▲]

Detailed reference viewed: 32 (13 ULg)
Full Text
Peer Reviewed
See detailPersistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease.
Gonzalez Aguilera, B.; Syrios, P.; Gadisseur, R et al

in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2016)

Phantom hCG refers to persistent mild elevations of hCG, leading physicians to unnecessary treatments whereas neither a true hCG nor a trophoblastic disease is present. We report the case of a 23-year-old ... [more ▼]

Phantom hCG refers to persistent mild elevations of hCG, leading physicians to unnecessary treatments whereas neither a true hCG nor a trophoblastic disease is present. We report the case of a 23-year-old woman with persistent low levels of serum hCG detected one month after miscarriage. As choriocarcinoma was suspected, a chemotherapy trial of methotrexate was prescribed, without any hCG reduction. Subsequently, laparoscopy ruled out a trophoblastic residue and the patient was referred to the Endocrine Unit for further investigations. While low levels of hCG were still detected in serum, no hCG was detected in the urine. In addition, when serum was processed in a HBT tube for revealing heterophilic antibodies, hCG was no longer detected. Such finding indicated the presence of phantom hCG due to heterophilic mouse antibodies interaction. This case raises the need of clinico-biological discussion to avoid inappropriate therapeutic decisions. Based on this case experience and after review of the literature, we suggest that current gynecological protocols for the diagnosis and treatment of trophoblastic disease should consider the inclusion of urinary hCG and/or a test for serum heterophilic antibodies when appropriate. [less ▲]

Detailed reference viewed: 33 (9 ULg)
Full Text
Peer Reviewed
See detailConcordance between iohexol and iothalamate plasma clearance
DELANAYE, Pierre ULg; JOURET, François ULg; LE GOFF, Caroline ULg et al

in American Journal of Kidney Diseases (2016)

Detailed reference viewed: 19 (4 ULg)
Full Text
Peer Reviewed
See detailReference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays
Bargnoux, Anne-Sophie; Kuster, Nils; Delatour, Vincent et al

in Archives of Pathology & Laboratory Medicine (2016), 140(2), 117-118

Detailed reference viewed: 45 (4 ULg)
Full Text
Peer Reviewed
See detailAdaptation posologique des médicaments et fonction rénale : Quel(s) estimateur(s) faut-il choisir?
DELANAYE, Pierre ULg; Flamant, M; CAVALIER, Etienne ULg et al

in Néphrologie & Thérapeutique (2016), 12(1), 18-31

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations ... [more ▼]

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations plus récentes, MDRD (pour Modified Diet in Renal Disease) et CKD-EPI (pour Chronic Kidney Disease Epidemiology). Les arguments mis en avant en faveur de l’utilisation de la formule de Cockcroft sont : qu’elle a été préférentiellement utilisée pour décider des adaptations posologiques avant la mise sur le marché des médicaments, qu’elle permettrait une meilleure prédiction du risque de survenue des effets indésirables a` l’accumulation des médicaments, qu’elle permettrait de limiter le surdosage médicamenteux chez la personne âgée. Dans cet article d’opinion, nous discutons les faiblesses de l’argumentaire des partisans du maintien de l’utilisation de la formule de Cockcroft dans le contexte de l’adaptation posologique, ainsi que les limites et le manque de fiabilité de cette formule. Nous soutenons la recommandation de la Haute Autorité de sante´ (HAS) sur l’utilisation systématique, en 2015, de l’équation CKD-EPI pour l’estimation du DFG. Lorsque le DFG est e´ value´ dans le but d’adapter la posologie d’un médicament, la désindexation de la surface corporelle est préférable. Compte tenu des difficultés d’estimation du DFG chez la personne âgée et chez les individus a` gabarit hors norme, nous recommandons d’utiliser en priorité dans ces populations, des médicaments pour lesquels un suivi pharmacologique est disponible, ou d’avoir recours à une méthode de référence de mesure du DFG. [less ▲]

Detailed reference viewed: 61 (5 ULg)
Full Text
Peer Reviewed
See detailSerum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations
Souberbielle, JC; CAVALIER, Etienne ULg; DELANAYE, Pierre ULg et al

in Clinica Chimica Acta (2015), 451 (Pt B)

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol ... [more ▼]

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol with a new automated direct assay on the Liaison XL platform in 888 healthy French Caucasian subjects aged 18–89 years, 32 patients with a surgically-proven PHPT, 32 pregnant women at the end of the first and at the end of the third trimester, and 24 dialysis patients before and after one year of supplementationwith vitamin D3 or placebo. The mean calcitriol concentration (±SD) in the healthy population was 52.9 ± 14.5 ng/L with a 95% CI interval of 29–83.6 ng/L. In PHPT patients, calcitriol concentration was 81.6±29.0 ng/L, 15 of them (46.9%) having a concentration N83.6 ng/L. In pregnant women, calcitriol was 80.4 ± 26.4 ng/L at the end of the first trimester, and 113.1±33.0 ng/L at the end of the third trimester, 12 (37.5%) and 26 (81.3%) of them having a calcitriol concentration N83.6 ng/L at the first and third trimesters respectively. In 14 dialysis patients, calcitriol was 9.5±7.7 ng/L and rose to 19.3 ng/L after one year of supplementation with 50,000 IU vitamin D3/month. In 10 other dialysis patients, calcitriol was 9.9±2.9 ng/L and remained stable (12.4±3.7 ng/L) after one year of placebo. In conclusion, this new automated calcitriol assay, in addition to presenting excellent analytical performances, gives the expected variations in patients compared to “normal” values obtained in an extensive reference population [less ▲]

Detailed reference viewed: 23 (5 ULg)
Full Text
Peer Reviewed
See detailA phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods
Bruyère, Olivier ULg; DEROISY, Rita ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(12), 2863-8

Summary In a randomized, cross-over study, once monthly administration of vitamin D3 was preferred over a once daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better ... [more ▼]

Summary In a randomized, cross-over study, once monthly administration of vitamin D3 was preferred over a once daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better compliance but without any significant difference in the increase in vitamin D levels. Introduction The aim of the present study was to compare a once-monthly administration of vitamin D3 to a daily administration of a fixed-dose combination of vitamin D3 and calcium during two treatment periods of 6 months. Methods One hundred volunteers aged 50 years old or older were randomized to receive either one drinkable ampoule containing 25,000 IU vitamin D3 (D-Cure®, SMB) once monthly (group VD) or one chewable tablet containing 1000 mg calcium carbonate+800 IU vitamin D3 (Steovit Forte®, Takeda) once daily (group VDCa) during 6 months. After the first 6 months of treatment, the groups were reversed according to the randomized cross-over design. Treatment compliance (i.e. the primary outcome), preference, acceptability and vitamin D levels and adverse events were all collected. Results For the two periods, the patients had a significantly higher compliance in the VD group than in the VDCa group (p<0.0001). During the study, 50 (56.8 %) patients preferred the VD treatment, 16 (18.2 %) patients preferred the VDCa, and for 22 (25.0 %) patients, neither treatment was preferred. At the end of the first 6 months of treatment, the mean (SD) increase of 25(OH)D was 6.57 ng/mL (8.19) in the VD group and 3.88 ng/mL (10.0) in the VDCa group (p=0.16 between groups). Conclusion In this study, a once-monthly administration of vitamin D3 was preferred over a once-daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better compliance but without any significant difference in the increase in vitamin D levels. [less ▲]

Detailed reference viewed: 64 (19 ULg)